An interventional study of cataract surgery with phacoemulsification in Efficacy and Complications, sponsored by Sheba Medical Center. Status unknown at 1 site in Israel. Per ClinicalTrials.gov, last updated 2009-07-21.
Sponsored by Sheba Medical Center · Not applicable, Interventional, and Treatment
To assess the risks of intra- and postoperative bleeding tendency associated with cataract surgery by phacoemulsification in patients on coumadin and antiaggregant treatments.
Design: Consecutive prospective study.
To assess the risks of intra- and postoperative bleeding tendency associated with cataract surgery by phacoemulsification technique in patients on coumadin and antiaggregant treatment Design: Consecutive prospective study.
1,726 studies on the registry are indexed under Cataract; 230 are open to participants now.
This study's planned enrollment of 75 is close to the median of 80 across 1,171 interventional studies indexed under Cataract.
Browse Cataract studies →Sheba Medical Center is the lead sponsor of 677 studies on the registry; 63 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patients under coumadin and antiaggregants operated by phacoemulsification
Procedure: cataract surgery with phacoemulsification
removal of cataract with phacoemulsification technique
safety and efficacy of cataract surgery with phacoemulsification under coumadin and antiaggregant treatment
Time frame: 3.5 years
other complications
Time frame: 3.5 years
This study is status unknown, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.